Hidradenitis Suppurativa - Pipeline Review, H1 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.
Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 4, 1, 8 and 1 respectively.
Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.
Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 4, 1, 8 and 1 respectively.
Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hidradenitis Suppurativa - Overview
Hidradenitis Suppurativa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hidradenitis Suppurativa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Celgene Corp
Cell Medica Ltd
Cellceutix Corp
Coherus BioSciences Inc
InflaRx GmbH
NeuClone Pty Ltd
Novartis AG
Panacea Biotec Ltd
Sandoz International GmbH
XBiotech Inc
Hidradenitis Suppurativa - Drug Profiles
adalimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJM-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MABp-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Hidradenitis Suppurativa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hidradenitis Suppurativa - Dormant Projects
Hidradenitis Suppurativa - Discontinued Products
Hidradenitis Suppurativa - Product Development Milestones
Featured News & Press Releases
Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa
Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress
Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition
May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland
May 04, 2016: NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales
Mar 02, 2016: Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab), Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting
Jan 06, 2016: AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Oct 05, 2015: AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
Sep 10, 2015: Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa
Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa
Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease
May 15, 2015: Abbvie Receives Orphan Drug Designation For Humira (Adalimumab) From The U.S. Food And Drug Administration For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa
Mar 17, 2015: Abbvie's Dermatology Leadership Showcased With Humira (Adalimumab) Data At American Academy Of Dermatology 2015 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hidradenitis Suppurativa - Overview
Hidradenitis Suppurativa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hidradenitis Suppurativa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Celgene Corp
Cell Medica Ltd
Cellceutix Corp
Coherus BioSciences Inc
InflaRx GmbH
NeuClone Pty Ltd
Novartis AG
Panacea Biotec Ltd
Sandoz International GmbH
XBiotech Inc
Hidradenitis Suppurativa - Drug Profiles
adalimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJM-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MABp-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Hidradenitis Suppurativa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hidradenitis Suppurativa - Dormant Projects
Hidradenitis Suppurativa - Discontinued Products
Hidradenitis Suppurativa - Product Development Milestones
Featured News & Press Releases
Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa
Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress
Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition
May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland
May 04, 2016: NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales
Mar 02, 2016: Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab), Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting
Jan 06, 2016: AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
Oct 05, 2015: AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
Sep 10, 2015: Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa
Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa
Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease
May 15, 2015: Abbvie Receives Orphan Drug Designation For Humira (Adalimumab) From The U.S. Food And Drug Administration For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa
Mar 17, 2015: Abbvie's Dermatology Leadership Showcased With Humira (Adalimumab) Data At American Academy Of Dermatology 2015 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Research Methodology
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.